Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain

10 juli 2017 uppdaterad av: Gary Peltz, Stanford University
The investigators hypothesize that perioperative administration of anakinra will reduce incisional pain by lowering the concentration of inflammatory mediators in surgical wounds. This knowledge is important because it suggests a new, previously unexplored pharmacological target for the control of postoperative incisional pain.

Studieöversikt

Status

Avslutad

Betingelser

Detaljerad beskrivning

This study will test whether administration of anakinra, an IL-1 receptor antagonist, will decrease pain and improve wound healing in patients undergoing vascular or orthopedic surgical procedures. The investigators will administer two doses of Anakinra via an injection under the skin, one dose one hour before surgery and a second dose on the first postoperative day (24 hours after surgery). The investigators will remove fluid from the surgical incisions using a small plastic catheter placed under skin during surgery and measure the amounts of pain- causing inflammatory mediators. The investigators will also measure the amount of pain the participant is experiencing using questions about pain intensity and by gently touching the incision to determine sensitivity of the incision site.

Studietyp

Interventionell

Inskrivning (Faktisk)

13

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • Stanford, California, Förenta staterna, 94305
        • Stanford Hospital and Clinics

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

-Patients 18 years of age and older presenting to the Stanford Preoperative Evaluation Clinic prior to elective orthopedic surgical procedures or elective vascular surgical procedures not involving the abdominal aorta or carotid arteries.

Exclusion Criteria:

Patients will be excluded from participation if they have one or more of the following conditions:

  1. Evidence of active local or systemic infection as demonstrated by fever, leukocytosis (white blood cell count > 11,000/ul), productive cough, new infiltrate on chest x-ray, or purulent drainage from any source
  2. End-stage renal disease
  3. A history of diabetic neuropathy
  4. A malignancy other than basal cell carcinoma of the skin or in situ carcinoma of the cervix within the previous 5 years
  5. Leukopenia (white blood cell count < 2,000/ul)
  6. Thrombocytopenia (platelet count < 100,000/ul)
  7. Abnormal liver function test result (aspartate aminotransferase or alanine aminotransferase level ≥1.5-fold the upper limit of normal)
  8. A history or infection with tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus
  9. Pregnant or breastfeeding

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Anakinra
Two subcutaneous injections of anakinra (IL-1ra) were given, the first one hour prior to surgery and the second 24 hours after surgery.
An injection of 100 mg Anakinra was administered 1 hour prior to surgery and again 24 hours following surgery.
Andra namn:
  • Kineret
Placebo-jämförare: Saline injection
Two subcutaneous injections of normal saline (same volume as the anakinra group injection) were given, the first one hour prior to surgery and the second 24 hours after surgery.
An injection of normal saline was administered 1 hour prior to surgery and again 24 hours following surgery.
Andra namn:
  • Inget annat namn

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Concentration Levels of Inflammatory Mediators IL-1 Receptor Antagonist (IL-1ra) Present in Human Wounds Following Surgery With and Without the Use of Anakinra.
Tidsram: Up to 72 hours following surgery
Tissue samples were collected at the surgical wound site at 3 time points during the 1st 72 hours following surgery. Tissue samples from subjects receiving placebo, and subjects receiving anakinra injections pre, and post op were analyzed for IL-1
Up to 72 hours following surgery

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of Participants With Analgesic Consumption During the 72 Hours Following Surgery
Tidsram: Up to 72 hours following surgery

Analgesic consumption is reported as the count of participants receiving each analgesic type. Comparisons between the placebo and active drug groups were made at the conclusion of the study.

PCA/IV: Patient controlled Analgesia/ Intravenous

Up to 72 hours following surgery
Post-operative Pain Intensity
Tidsram: Up to 72 hours following surgery
Pain was measured on Day 1 and day 2 following surgery using a VAS scale at rest and on stimulation with Visual Analog Scale (VAS) of 1-10 (1=no pain and 10=worst pain)
Up to 72 hours following surgery
Count of Participants Experiencing Wound Infection in the Study From Surgery Till the Time of Discharge From the Hospital
Tidsram: Up to 72 hours following surgery plus 3 weeks follow-up
Evaluation of the surgical wound for symptoms of wound infection was made every day during hospitalization. Records from the first post-operative clinic visit were also evaluated for evidence of wound infection.
Up to 72 hours following surgery plus 3 weeks follow-up
Count of Participants With Venous Thrombosis After Surgery During Hospitalization
Tidsram: Up to 72 hours following surgery plus 3 weeks follow-up
Evaluation of the surgical wound for symptoms of venous thrombosis was made every day during hospitalization. Records from the first post-operative clinic visit were also evaluated for evidence of venous thrombosis.
Up to 72 hours following surgery plus 3 weeks follow-up
Assess Rates of Wound Dehiscence
Tidsram: Up to 72 hours following surgery plus 3 weeks follow-up
Evaluation of the surgical wound for symptoms of wound dehiscence was made every day during hospitalization. Records from the first post-operative clinic visit were also evaluated for evidence of wound dehiscence.
Up to 72 hours following surgery plus 3 weeks follow-up
Total Length of Hospital Stay
Tidsram: Up to approximately 5 days maximum (admittance to discharge)
Total length of hospital stay for patients enrolled in the study.
Up to approximately 5 days maximum (admittance to discharge)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Robert L Lobato, MD, Stanford U

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 oktober 2011

Primärt slutförande (Faktisk)

1 maj 2013

Avslutad studie (Faktisk)

1 juni 2013

Studieregistreringsdatum

Först inskickad

1 november 2011

Först inskickad som uppfyllde QC-kriterierna

7 november 2011

Första postat (Uppskatta)

8 november 2011

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

9 augusti 2017

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 juli 2017

Senast verifierad

1 juli 2017

Mer information

Termer relaterade till denna studie

Nyckelord

Andra studie-ID-nummer

  • SU-10312011-8587

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera